James F. Barlow - Jun 14, 2024 Form 4 Insider Report for Arcturus Therapeutics Holdings Inc. (ARCT)

Role
Director
Signature
/s/ Ilan Katz, attorney-in-fact
Stock symbol
ARCT
Transactions as of
Jun 14, 2024
Transactions value $
$0
Form type
4
Date filed
6/18/2024, 09:00 PM
Previous filing
Aug 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARCT Common Stock Options Exercise $0 +3.13K +31.31% $0.00 13.1K Jun 14, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARCT Deferred Stock Units Options Exercise $0 -3.13K -100% $0.00* 0 Jun 14, 2024 Common Stock 3.13K $0.00 Direct F1, F2
transaction ARCT Stock option (right to buy) Award $0 +15K $0.00 15K Jun 14, 2024 Common Stock 15K $31.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.
F2 Represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.
F3 Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.